United Therapeutics Corp (NASDAQ: UTHR) started the day on Wednesday, with a price decrease of -4.78% at $352.58, before settling in for the price of $370.26 at the close. Taking a more long-term approach, UTHR posted a 52-week range of $208.62-$377.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 8.02% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 8.15%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 24.38%. This publicly-traded company’s shares outstanding now amounts to $47.04 million, simultaneously with a float of $43.71 million. The organization now has a market capitalization sitting at $15.69 billion.
United Therapeutics Corp (UTHR) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. United Therapeutics Corp’s current insider ownership accounts for 1.75%, in contrast to 104.71% institutional ownership. According to the most recent insider trade that took place on Oct 21 ’24, this organization’s CFO AND TREASURER sold 7,782 shares at the rate of 366.99, making the entire transaction reach 2,855,916 in total value, affecting insider ownership by 6,426.
United Therapeutics Corp (UTHR) Earnings and Revenue Records
United Therapeutics Corp’s EPS increase for this current 12-month fiscal period is 24.38% and is forecasted to reach 28.25 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 13.00% through the next 5 years, which can be compared against the 8.15% growth it accomplished over the previous five years trading on the market.
United Therapeutics Corp (NASDAQ: UTHR) Trading Performance Indicators
Let’s observe the current performance indicators for United Therapeutics Corp (UTHR). It’s Quick Ratio in the last reported quarter now stands at 4.18. The Stock has managed to achieve an average true range (ATR) of 9.41. Alongside those numbers, its PE Ratio stands at $16.20, and its Beta score is 0.56. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.99. Similarly, its price to free cash flow for trailing twelve months is now 17.81.
In the same vein, UTHR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 21.77, a figure that is expected to reach 6.53 in the next quarter, and analysts are predicting that it will be 28.25 at the market close of one year from today.
